Salute e Benessere

Oncolytics Biotech® Recaps 2023 Accomplishments, Provides Outlook for 2024

Positive Clinical and Translational Data: "Positive, early results from the Phase 1/2 GOBLET study in three gastrointestinal cancers - pancreatic, anal, and colorectal - showed that the combination of pelareorep and atezolizumab produced clinically meaningful improvements in response rates and survival timelines that are notably improved compared to historical results with no toxicity concerns. Translational data from studies in solid tumors, breast, pancreatic, and colorectal cancers…
PR Newswire
04/01/2024

Samsung Biologics selects Rapid Micro Biosystems' Growth Direct® platform to…

Companies share commitment to innovating quality control processes to meet biomanufacturing challenges such as scale, data integrity and accelerating time to market ®platform to automate its microbial quality control processes to deliver increased efficiency, more robust data integrity and scalable quality control operations. “Samsung Biologics is a leading global contract development and manufacturing organization (CDMO) and has demonstrated an unwavering commitment to automation and...
Nasdaq GlobeNewswire
04/01/2024

Zymeworks Outlines Strategic Priorities and Outlook for 2024 and 2025

Company well-positioned for further progress and broadening of R&D pipeline Cash resources of approximately $455 million as of December 31, 2023 (unaudited)Expected cash runway, including proceeds from recent private placement, into 2H 2027Top-line data readout from the Phase 3 trial evaluating zanidatamab in HER2-positive gastroesophageal adenocarcinoma (GEA), HERIZON-GEA-01, expected in 2024Expected regulatory reviews ongoing during 2024 for zanidatamab in second-line...
Nasdaq GlobeNewswire
04/01/2024

Zymeworks Announces Additional Leadership Appointments

Dr. Jeffrey Smith named Executive Vice President and Chief Medical Officer Dr. John Fann promoted to Senior VP, Process SciencesSeven new Vice Presidents appointed, underscoring commitment to leadership development VANCOUVER, British Columbia, Jan.04, 2024(GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat...
Nasdaq GlobeNewswire
04/01/2024

Novo Nordisk enters into research collaborations with Omega Therapeutics and…

Omega collaboration will leverage the company's platform to develop an epigenomic controller as part of a new approach to obesity managementCellarity collaboration will build upon initial work and engage the company's platform to develop a small molecule therapy in metabolic dysfunction-associated steatohepatitis (MASH)First two research programmes signed under existing partnership between Novo Nordisk and Flagship PioneeringNovo Nordisk will reimburse R&D costs and each company and...
Nasdaq GlobeNewswire
04/01/2024

Biocomposites' investee Renovos Biologics receives FDA Breakthrough Device…

Dr Agnieszka Janeczek, Chief Executive Officer of Renovos Biologics, said: "We are very pleased with the Breakthrough Device Designation from the FDA, being among just one hundred or so companies granted this designation in orthopaedics since the programme's launch in 2015. This designation is a major milestone in our development journey. The accelerated regulatory feedback and prioritised review will shorten the time to market and allow faster access to expanded treatment options for…
PR Newswire
04/01/2024

Zendure and solarlab.es Forge Sustainable Energy Partnership, Debuting in Leroy…

solarlab.es specializes in portable solar panels designed for self-installation. Their mission to provide sustainable energy solutions aligns perfectly with Zendure's vision to be a Clean EnergyTech platform that sustains communities and families. Their products, designed for easy installation and known for their lightweight design, cater to a demographic of 30-65-year-olds with medium to high socioeconomic status, predominantly male, across Spain, France, and Germany. solarlab.es ...
PR Newswire
04/01/2024

Alex Therapeutics Reports Positive Results from the Randomized-Controlled Trial…

The COMPANION study enrolled 108 participants from across the United States in a randomized, controlled, parallel-group clinical investigation evaluating the impact of Almee on the psychological symptom burden in adults diagnosed with PF. Living with a deadly disease for which there is currently no curative treatment available has a negative impact on mental health and quality of life3; the aim of Almee is to provide personalized and accessible psychological support for these patients. The...
PR Newswire
04/01/2024

Versius customer reach increases as CMR Surgical closes 2023 with strongest…

Versius customer reach increases as CMR Surgical closes 2023 with strongest quarter on recordAfter a record quarter, CMR closes the year with a Versius global install base more than 50% higher than 2022Over 17,000 surgical procedures completed using Versius, representing a procedural growth rate of over c.60% in 2023, compared with 2022, with an increasing number of complex surgeries being undertaken with VersiusContinued expansion into new markets in Europe, Asia, Middle East,...
Nasdaq GlobeNewswire
04/01/2024

Nexstim Agrees on a Strategic Investment into a Management Services Organization…

Press release, Helsinki, 4 January 2024 at 9 AM (EET) Nexstim Agrees on a Strategic Investment into a Management Services Organization of a New Jersey Based Clinic Providing Treatments for Depression Patients Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") group US private equity company Nexstim Investments, LLC has signed an agreement regarding a strategic alliance with and a minority ownership in a management services organization (MSO) Siddhartha Center for Clinical…
Nasdaq GlobeNewswire
04/01/2024

Monthly information related to total number of voting rights and shares…

Monthly information related to total number of voting rights and shares composing the share capital _ December 31, 2023 Article 223-16 of general regulation of French Autorité des Marchés FinanciersListing markets:Euronext Paris from Euronext (Market segment C - ISIN Code: FR001400K4B1- Symbol: PHXM) &Nasdaq Global Select Market in the United-States (Symbol: PHXM) Website : www.phaxiam.com DateTotal of shares composing the share capitalTotal of brut(1)...
Nasdaq GlobeNewswire
03/01/2024

Galapagos establishes strategic collaboration with BridGene Biosciences to…

Strategic collaboration and licensing agreement further strengthens Galapagos' growing early-stage pipeline in oncology precision medicineCollaboration leverages Galapagos' expertise in small molecule drug discovery and development with BridGene's innovative discovery platform for “hard-to-drug” targetsGalapagos to pay up to $27 million in upfront and preclinical milestone payments to BridGene Mechelen, Belgium; 3 January 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ:...
Nasdaq GlobeNewswire
03/01/2024

Alkermes to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Alkermes Contact: Jamie ConstantineInvestor Relations+1 781 873 2402 Alkermes Contact: Jamie ConstantineInvestor Relations +1 781 873 2402 Logo -https://mma.prnewswire.com/media/616416/Alkermes_plc_Logo.jpg View original content: https://www.prnewswire.co.uk/news-releases/alkermes-to-present-at-the-42nd-annual-jp-morgan-healthcare-conference-302025519.html
PR Newswire
03/01/2024

The Global Disinfection Robots Market Booms as Demand Soar, Triggering…

Browse in-depth TOC on "Disinfection Robots Market" Browse in-depth TOC on "Disinfection Robots Market" 399 – Pages 133 - Tables 132 - Figures Disinfection Robots Market Report Scope Evolution of Automated Guided Vehicles & Automated Mobile Robots Uplifting the Market Opportunities Automated mobile robots (AMR) are used for cleaning and disinfection in distribution centers, hospitality services, grocery stores, hospitals, healthcare facilities, and more...
PR Newswire
03/01/2024

Groupe Casino: Fairness opinion for existing shareholders on the Casino Group's…

Fairness opinion for existing shareholders on the Casino Group's financial restructuring projectParis, 3 January 2024Following on from the report made available to shareholders by Sorgem Evaluation as independent expert, the Group would like to reiterate the main conclusions of this report, which concluded that the restructuring plan is fair to current shareholders ( link ).According to Sorgem's report, without implementation of the restructuring plan (see Appendix), the Group's...
Nasdaq GlobeNewswire
03/01/2024

Europe Disposable Gloves Market to Witness Robust Expansion, More than $4…

Browse in-depth TOC on "Europe Disposable Gloves Market" Browse in-depth TOC on "Europe Disposable Gloves Market" 340 – Pages 79 - Tables 174 - Figures Europe Disposable Gloves Market Report Scope TheEuropedisposable gloves market caters to various industries, including healthcare, food & beverage, pharmaceuticals, manufacturing, and cleaning & sanitation services. Each industry segment has distinct requirements, influencing the type of disposable gloves used...
PR Newswire
03/01/2024

Transplant Diagnostics Market to Attain a Valuation of USD 2.3 billion by 2031…

Patients with chronic kidney disorders have a feasible and frequently chosen therapeutic option in transplantation. The worldwide transplant diagnostics market is expected to provide attractive prospects for research and development in noninvasive transplant diagnostic techniques, immunosuppressive drugs, and post-transplant care. Vendors are developing new tests and antigen products in order to broaden their range of offerings. Patients with chronic kidney disorders have a feasible and...
PR Newswire
03/01/2024

Turn Biotechnologies' Expanded eTurna™ Delivery Platform Designed to Solve…

The proprietary ionizable lipids used in the eTurna™ delivery platform are safer as they are biodegradable, non-toxic and clear the body faster, while providing higher encapsulation capacity and cargo loading. Since the platform can utilize PEG-free stabilizing components, the delivery system minimizes or eliminates immunogenicity associated with PEG lipids currently used in LNPs. The platform's optimized particle size also means higher transfection rates for the therapies it delivers. The...
PR Newswire
03/01/2024

Caidya Welcomes Jay Roberts to its Board of Directors

"We are thrilled to have Jay join our Board of Directors and bring his extensive experience and leadership in the biopharmaceutical industry," said Lingshi Tan, Ph.D., Chairman and CEO of Caidya. "With our continued focus on serving the needs of emerging biotechs, Jay's background and understanding of customer value creation for the biopharmaceutical industry will be instrumental in guiding Caidya's strategic direction and driving our growth initiatives. In addition, Jay's…
PR Newswire
03/01/2024

AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for…

AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseasesABATE Phase 1b/2 AD trial of ACI-24.060 completed enrollment of cohorts 1 and 2 and is expected to complete cohort 3 in January; 6-month and 12-month amyloid PET data expected in H1 & H2 2024, respectivelyReTain Phase 2b clinical trial of ACI-35.030 in preclinical AD being launched now by partnerVacSYn Phase 2 PD trial of ACI-7104.056 completed enrollment of cohort 1...
Nasdaq GlobeNewswire
03/01/2024

Alkermes Announces Topline Results From Long-Term, Open-Label Safety and…

In this global, open-label extension study, 523 participants received at least one dose of LYBALVI and 35.9% of participants completed the four-year treatment period. The safety profile of LYBALVI was consistent with previous studies. Patients' symptoms of schizophrenia or bipolar I disorder remained stable with up to four years of treatment with LYBALVI, as measured by the Clinical Global Impression of Severity (CGI-S) scale (mean change from baseline in CGI-S score of -0.28). Long-term…
PR Newswire
03/01/2024

iTeos to Present at the 42nd Annual J.P. Morgan Healthcare Conference

ndAnnual J.P. Morgan Healthcare Conference being held in San Francisco, CA on Wednesday, January 10, 2024 at 3:00 p.m. PST (6:00 p.m. EST). A live webcast of the presentation will be available on the Investors section of the Company's website at https://www.iteostherapeutics.com. An archived replay will be available for approximately 30 days following the presentation. About iTeos Therapeutics, Inc. iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the...
Nasdaq GlobeNewswire
03/01/2024

Ribo partners with Boehringer Ingelheim to develop new treatments for people…

Ribo's cutting edge RIBO-GalSTAR™ platform enables the development of RNAi therapeutics targeting disease-causing genes specifically in hepatocytes by silencing their messenger RNAs (mRNAs). This approach has the potential to treat diseases addressing previously inaccessible drug targets. Ribo's cutting edge RIBO-GalSTAR™ platform enables the development of RNAi therapeutics targeting disease-causing genes specifically in hepatocytes by silencing their messenger RNAs (mRNAs). This approach…
PR Newswire
03/01/2024

Global Digital Genome Market Set to Hit US$ 92.93 Bn by 2030, Growing at 19.58%…

Request Sample PDF of the Report: https://www.kingsresearch.com/request-sample/digital-genome-market-294 Request Sample PDF of the Report: https://www.kingsresearch.com/request-sample/digital-genome-market-294 The global digital genome market is expected to undergo substantial growth and transformation from 2023 to 2030. Key drivers of this growth include the integration of artificial intelligence (AI) and machine learning in genomic analysis, enhancing data interpretation accuracy and...
PR Newswire
03/01/2024
Altri  Comunicati